Forum Topic Clinical Trials
  • Conversation: Sanofi, Novartis, and GSK prioritize PROs

    • July 26, 2018 12:37 PM BST
    • Sanofi, Novartis, and GSK prioritize PROs

      Clinical trials are no longer about hard clinical endpoints. Payers are increasingly demanding patient-centered outcomes as a prerequisite to approve access to new medicines. Once regarded as ‘nice to have’ measures, PROs are increasingly seen as essential tools.
      eyeforpharma’s latest whitepaper provides an in-depth analysis of PROs across research, regulation and the real-world, and looks to a future where patient engagement is the start point for clinical development, not just an endpoint.
      Read the full whitepaper here - http://bit.ly/2LcP6aR
      Leaders from Sanofi, Novartis, Celgene, GSK, Takeda and others discuss:
      • Why patient insights are the blueprint for effective PRO design
      • How effective are PROs in securing patient access?
      • PROs: The future of clinical trials?
      Download your copy for free here - http://bit.ly/2LcP6aR
      Enjoy!

Add Reputation

Do you want to add reputation for this member by this post?

or cancel